Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BOYDSense has developed a proprietary miniaturized breath analysis device that uses MOx sensors to detect volatile organic compounds as biomarkers of chronic diseases. Their first application targets non-invasive glucose monitoring for diabetes management. Clinical studies are ongoing, with presentations at international congresses such as DTM 2024. The technology shows promise for expanding into other indications like sepsis and fatty liver disease, aiming to provide cost-effective, pain-free health monitoring solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BOYDSense.